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This document is an official document of the American
College of Cardiology (ACC)/American Heart Association
(AHA) Task Force on Performance Measures. The task force
formed a work group to address the challenges of perfor-
mance measurement and reperfusion therapy.
1. Introduction
Acute reperfusion therapy, either with fibrinolytic therapy or
percutaneous coronary intervention (PCI), is one of the most
important treatments for patients with ST-segment elevation
myocardial infarction (STEMI). Randomized clinical trials
have shown that reperfusion therapy provided to eligible
patients reduces the risk of death due to all causes (1). The
timeliness of reperfusion therapy is of central importance,
because the benefits of therapy diminish rapidly with delays
in treatment. Thus, ACC/AHA guidelines recommend that
fibrinolysis be provided within 30 minutes of first medical
system contact and that primary PCI be provided within 90
minutes of first medical system contact for patients pres-
enting with STEMI (1). These guideline recommendations
have been translated into performance measures that are
reported to the public by the Centers for Medicare &
Medicaid Services (CMS) and the Joint Commission (2,3).
Measurement of the time to reperfusion therapy involves
challenges that have hampered the acceptance of these
performance measures among some clinicians and hospitals.
On the basis of field testing of the existing measures, the most
controversial aspects of the measures include the character-
istics of the measures’ population (ie, inclusions and exclu-
sions) and the determination of the time at which measure-
ment stops for patients receiving primary PCI. Furthermore,
the current measures do not address some components of the
quality of reperfusion (eg, appropriateness), do not include
allimportant segments of the population receiving reperfusion
(eg, those transferred from one facility to another for treat-
ment), or do not include an assessment of prehospital factors
(ie, starting measurement at the time of first system contact).
To address these challenges, a work group was convened with
the goals of evaluating the current CMS and Joint Commis-
sion time-to-reperfusion measures; considering modifications
to optimize measurement; assessing the alignment of the
CMS and Joint Commission measures with those used by the
National Cardiovascular Data Registry (NCDR) CathPCI
Registry; and proposing further measures to increase the
scope of the assessment of reperfusion therapy for STEMI.
This work group included representatives from the ACC/
AHA Performance Measures Task Force; the ACC/AHA Prac-
tice Guidelines Task Force; the NCDR; the AHA’s Get With the
Guidelines program; the Society of Cardiovascular Angiography
and Interventions; CMS; and the Joint Commission. Members of
the work group have expertise in a wide range of relevant areas,
including interventional cardiology, general cardiology, emer-
gency medicine, performance-measure development and imple-
mentation, and clinical registry development.
The present document provides a historical perspective on
the measurement of time to reperfusion, describes the balance
of characteristics necessary for a usable performance measure
of reperfusion therapy, summarizes the deliberations of the
work group concerning several important issues in the mea-
surement of time to reperfusion, and provides recommenda-
tions for additional performance measures for reperfusion
therapy. It is intended to clarify the challenges related to
measuring this important aspect of care for patients with
STEMI, provide recommendations for optimizing the current
reperfusion measures, and suggest the general characteristics
of more comprehensive measures of reperfusion therapy.
2. History of the Time-to-Reperfusion
Performance Measures
As a result of the efficacy of acute reperfusion therapy for
STEMI and the importance of the timeliness of therapy, time
to reperfusion emerged as an indicator of the quality of care
for patients with STEMI. Reperfusion therapy has been a
focus of quality assessment since the early 1990s, when the
Health Care Financing Administration (HCFA, now CMS)
launched the Cooperative Cardiovascular Project pilot study
and the National Heart, Lung, and Blood Institute–supported
National Heart Attack Alert Program was initiated (4,5).
These programs were designed in part to measure the quality
of reperfusion therapy with fibrinolysis for patients with
STEMI. A measure of the proportion of ideal candidates who
received fibrinolysis within 12 hours of presentation was
evaluated in the Cooperative Cardiovascular Project, but this
measure was not included in later projects, in part because of
challenges in identifying a robust denominator for the mea-
sure (4). However, time to reperfusion for eligible STEMI
patients persisted as a primary measure throughout the
Cooperative Cardiovascular Project.
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The CMS continued to include the time to reperfusion for
STEMI as a performance measure in the National AMI Project,
which assessed the quality of care for acute myocardial infarc-
tion nationwide between 1998 and 2001 (6–8). Because primary
PCI had emerged as an evidence-based reperfusion strategy, the
measures for these efforts included measures of the time to
reperfusion for both fibrinolytic therapy and primary PCI. As
with the Cooperative Cardiovascular Project, the measures for
these projects only assessed the time to therapy among treated
patients and did not include an assessment of the use of
reperfusion among all potentially eligible candidates (underuse)
or the use of reperfusion therapy among patients who were not
candidates for therapy (overuse).
Since the initiation of the CMS measurement projects,
national performance for the timeliness of acute reperfusion
has generally improved. Between the Cooperative Cardiovas-
cular Project (1994 to 1995) and the National AMI Project
Baseline (1998 to 1999), the mean time to fibrinolysis among
eligible patients improved by 7 minutes and the time to PCI
by 12 minutes (7). Between 1998 to 1999 and 2000 to 2001,
fibrinolysis times increased slightly (by 4 minutes, to a
median of 45 minutes), whereas time to PCI continued to
improve (by 19 minutes, to a median of 107 minutes) (6).
Thus, although data on national trends in the timeliness of
reperfusion have been encouraging, there are clearly persis-
tent gaps in the provision of reperfusion therapy that justify
ongoing measurement.
Since the time of the National Heart Care Project, reper-
fusion measures have evolved. In 2002, CMS and the Joint
Commission collaborated to develop aligned measures for
use by both organizations. These measure sets included
institutional times to treatment for patients with STEMI who
received therapy, as well as the proportion of patients treated
in a timely fashion for both fibrinolysis and PCI. Although for
a time, the threshold to define timely PCI was set at 120
minutes, more definitive recommendations contained in the
STEMI guidelines motivated a revision to a 90-minute
threshold in July 2006 (9). Beginning in 2004, the measures
reported institutional mean times to reperfusion; however,
because of the undue influence of outliers on the mean,
median times were substituted in January 2006.
In 2006, the ACC/AHA published the specifications of
performance measures for acute myocardial infarction, which
included several measures concerning the provision of reper-
fusion therapy for STEMI (10). These measures included
time-to-reperfusion measures for fibrinolysis and primary
PCI that were closely aligned with existing CMS and Joint
Commission measures, with 2 notable exceptions. First, the
ACC/AHA measures excluded patients for whom a clinical
reason for delaying therapy was documented. Subsequently,
the CMS and Joint Commission adopted this same exclusion.
Second, the ACC/AHA performance measure set included a
measure of the provision of reperfusion therapy to eligible
candidates for treatment, which to this point has not been
adopted by CMS and the Joint Commission.
Several constituencies have promoted timely reperfusion
as a measure of quality of care, some of which report these
statistics nationally. Currently, they are part of the CMS and
Joint Commission core performance-measures set for acute
myocardial infarction (2). These measures, which include
institutional median times to fibrinolysis and PCI, as well as
the proportion of patients receiving fibrinolysis within 30
minutes of arrival and PCI within 90 minutes of arrival, are
reported to the public on the Hospital Compare World Wide
Web site (11). The NCDR also includes measures of timely
reperfusion for primary PCI, albeit using somewhat different
numerator and denominator definitions and different data-
element definitions (12). The AHA’s Get With the Guidelines
program has also collected time-to-reperfusion data for pa-
tients with STEMI (13). Because of the known gaps in
reperfusion therapy quality (14) and an understanding of the
factors associated with faster PCI times (15), the ACC, in
collaboration with several other national organizations,
launched the D2B (Door-to-Balloon) Alliance for quality,
which was designed to disseminate effective strategies to
improve the time to primary PCI (16). With increasing public
availability of data on quality measures and a growing
penetration of pay-for-performance programs based on
widely used performance measures, an increasing focus on
timely reperfusion measures and the consistency of the
definitions of these measures has been inevitable.
3. Attributes of Performance Measures
of Time to Reperfusion
Performance measures and guideline recommendations are
not synonymous (17). Guidelines identify processes of care
that should generally be used in patients with a given
condition, with varying levels of the strength of recommen-
dations to be considered by the clinician. Performance mea-
sures identify aspects of care for which the failure to provide
a particular process of care is judged as poor clinical
performance. An understanding of the characteristics of
performance measures provides fundamental insights into the
process of developing and modifying measures used for the
assessment of clinical performance.
Timely reperfusion for STEMI, defined in current guidelines
as the provision of fibrinolysis within 30 minutes of first medical
contact or of PCI within 90 minutes of first medical contact, has
been incorporated in the guidelines as a class I recommendation
on the basis of the wealth of data demonstrating the association
of rapid treatment with better outcomes (1). Such strong,
evidence-based support alone is necessary but not sufficient to
consider this process of care as a performance measure. The
criteria for robust process performance measures have been
articulated by the ACC/AHA Performance Measures Task Force
(17). Beyond support by clinical trials and guidelines, the task
force report suggests that performance measures must also be 1)
interpretable; 2) actionable; 3) characterized by well-defined
numerators and denominators; 4) valid (face, construct, and
content); 5) reliable/reproducible; and 6) feasible. In general,
although current reperfusion measures generally meet these
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criteria, certain aspects of these attributes merit further
discussion.
Despite well-defined numerators and denominators, no
performance measure will perfectly classify eligible patients
or appropriately ascertain treatment in all patients. Like
diagnostic tests, performance-measure numerators and de-
nominators have variable sensitivity and specificity, and in
general, improvements in sensitivity usually result in lower
specificity and vice versa. Thus, changes in the denominator
that increase sensitivity will ensure that a larger number of the
patients who are truly eligible to receive a process of care will
be included in the measure; however, such a change will
simultaneously increase the inclusion of patients who are
ineligible for treatment. For example, a relatively stringent
definition of the electrocardiographic (ECG) criteria needed
for inclusion in the measure will increase the likelihood that
patients included in the measure truly have STEMI. On the
other hand, such criteria will necessarily result in larger
numbers of patients with ST-segment elevation who are
excluded inappropriately.
The manner in which data are collected has an important
impact on the feasibility, cost, and performance of the measure.
The underlying data for the performance measures for CMS and
the Joint Commission have been designed to allow for abstrac-
tion by nonclinicians. Although in some cases, individuals with
clinical experience may perform the abstraction, this is not
uniformly the case. Although abstractors receive training to
optimize the accuracy of abstraction, they may not be able to
apply clinical decision-making skills during abstraction. Further-
more, the burden of abstraction depends substantially upon the
detail and construction of the underlying data definitions and the
need to adjudicate conflicts in clinical documentation. Using the
time-to-reperfusion performance measures as an example, inclu-
sion ECG criteria are not ascertained by a direct interpretation of
the ECG; rather, the abstractor reviews the medical record and
determines whether the interpretations provided by the clinicians
in the record indicate that the patient meets ECG criteria for
acute reperfusion. Abstraction rules have been developed to
facilitate the adjudication of conflicts in documented interpreta-
tions. As another example, in defining the time at which a
reperfusion device is used, the data-element and abstraction
instructions must account for the variability with which these
data are recorded in medical records from numerous institutions.
The data elements for process performance measures
should also be designed to minimize the extent to which
documentation can be used to avoid the spirit of the measure
(ie, gaming). Performance measurement may unintentionally
generate incentives for creative recordkeeping, particularly
when the stakes of measurement are high and the perceived
risks posed to the patient are low. Both concerns about
gaming and the extent to which even the possibility of
gaming may undermine the credibility of a measurement
system support the development of data elements and defini-
tions that are resistant to gaming. Credible and transparent
audit processes would also reduce the likelihood of gaming.
Finally, the wide range of organizations interested in
performance measurement has led to the proliferation of
numerous measures sets for different conditions, which in
many circumstances are not aligned. The lack of alignment
among measures sets increases the burden of documentation
and data collection, inevitably resulting in confusion. Further-
more, failure of alignment may have important implications
for performance-based rankings. A recent analysis comparing
time-to-PCI measures between the CMS and Joint Commis-
sion measures and the NCDR measures found only moderate
agreement between door-to-PCI times between the 2 mea-
sures in the same hospitals (18). The benefits of alignment are
therefore substantial. This alignment should take into account
not only the measure macrospecifications (eg, numerator and
denominator statements) but also the microspecifications (eg,
data-element definitions). A failure of alignment at either
level results in systematic differences in the patient popula-
tions included and the assessments of the processes of care
applied, as well as differences in the measured performance
within an institution.
In summary, performance measures differ significantly
from guideline recommendations in that performance mea-
sures must meet multiple additional criteria beyond a strong
basis in evidence. The development of performance measures
must also include a consideration of the inevitability of some
degree of misclassification; the burden of abstraction neces-
sary for measurement; the possibility of gaming; and the
importance of measure alignment. These factors were explic-
itly considered in the discussions of the present committee
about possible modifications to the time-to-reperfusion mea-
sures. Ultimately, it is also important to keep in mind the
goals of the reperfusion performance measures, which are to
provide a quantitative assessment of this important process of
care, introduce accountability for performance in providing
timely reperfusion, improve the quality of care, and reduce
adverse outcomes of patients with STEMI.
4. Specific Challenges to Measuring
Time to Reperfusion
During the implementation of the CMS and Joint Commis-
sion performance measures for acute reperfusion for STEMI,
several issues have been raised regarding the characteristics
of the measures and the data elements underlying the mea-
sures. Although the range of questions that has emerged is
broad, 3 themes merit specific consideration: the measure
inclusions, the measure exclusions, and the determination of
the time at which measurement stops for patients receiving
primary PCI. The present work group addressed each of these
explicitly in its discussions and recommendations.
4.1. Measures Inclusions
Reperfusion measures will ideally include all patients who were
treated with a primary reperfusion strategy for STEMI. These
patients should be treated as rapidly as possible. The criteria for
inclusion in the current CMS and Joint Commission time-to-
reperfusion performance measures are delineated in Appendix
2103JACC Vol. 52, No. 24, 2008 Masoudi et al.
December 9, 2008:2100–12 ACC/AHA Performance Measurement and Reperfusion Therapy
A, Table A1. Two aspects of these criteria merit discussion.
First, as mentioned above, the ECG findings are derived from
abstraction of the ECG interpretation in the medical record
rather than a de novo interpretation of the ECG by a clinician.
Although ECG interpretations by clinicians may more precisely
identify those patients who meet strict guidelines-based criteria
for primary reperfusion strategies, this approach is currently not
feasible because of the resources required for clinician abstrac-
tion of the primary data. Furthermore, because abstraction
focuses on the documented interpretation(s) of the ECG tracing
rather than the ECG itself, the definitions used to guide the
abstractors in the ECG interpretation are necessarily complex.
The CMS and the Joint Commission have recently streamlined
this data element.
Regardless of the definitions used, any criteria used to classify
ECGs will misclassify patients to some extent. For example, a
tracing that shows 1.5 mm of ST-segment elevation in inferior
leads II, III, and aVF with reciprocal ST-segment depressions in
the anterior leads would be classified appropriately, presuming
the documentation of the interpretation accurately reflects these
findings. However, for the purposes of measurement, the tracing
could be classified as not showing ST-segment elevation for
several reasons, including vague documentation (eg, “ST-
segment abnormalities in the inferior and anterior leads”) or
even misinterpretation of the tracing (eg, “ST-segment elevation,
consider pericarditis”). Although definitions based on the inter-
pretations of documented ECGs are likely to have more potential
for misclassification than those based on standardized criteria
applied to de novo tracing interpretations, the latter approach is
not plausible owing to the resources necessary to achieve this
standard.
Second, the ECG criteria for the CMS and Joint Commis-
sion measures apply only to the ECG obtained closest to
arrival at the hospital, including any ECGs obtained within
the hour before arrival. Thus, those patients who develop
STEMI after presenting with an ECG closest to arrival that is
not consistent with STEMI are not included. Ideally, a
comprehensive assessment of performance in delivering
timely reperfusion would include all patients with STEMI.
However, whereas the time of hospital arrival can be identi-
fied relatively easily in the medical record, determining the
appropriate “start” time for patients who develop STEMI
after their presentation is relatively challenging. The current
CMS and Joint Commission measures attempt to strike a
balance between the interest in including as many patients as
possible and the practical aspects of the limitations of medical
records abstraction. However, this criterion represents an area
of nonalignment with the measures of time to reperfusion
currently used in the NCDR ACTION-Get With the Guide-
lines and CathPCI registries, which include patients with
STEMI that develops while they are in the hospital.
4.1.1. Measures Inclusions—Work Group
Conclusions
1. The work group supports current efforts by CMS and the
Joint Commission to simplify the current ECG interpreta-
tion data element to the extent possible, acknowledging
that it must provide adequate guidance to nonclinical
abstractors in identifying possible candidates for acute
reperfusion. These modifications should be tested to de-
termine the impact on the populations of patients included
in the measures.
2. The goals of prompt reperfusion are to restore blood flow
in a completely occluded coronary artery, clinically man-
ifested as a STEMI. Ideally, the performance measure
would include those patients with STEMI that evolves
after arrival at the hospital or that develops in the hospital.
Until it is possible to enact this modification in practice,
the patient population in the current CMS and Joint
Commission measure should be contained entirely within
the populations of the NCDR and AHA Get With the
Guidelines programs to the extent possible, which will
facilitate comparisons between measures sets and
institutions.
4.2. Measures Exclusions
Even among those patients presenting with STEMI, not all
are appropriate for inclusion in a performance measure of
time to reperfusion. Accordingly, some patients meeting the
above inclusion criteria are ultimately excluded from the
measures denominators on the basis of the criteria enumer-
ated in Appendix A2, 3 of which merit further examination.
First, patients who present at one hospital and are trans-
ferred for reperfusion (usually PCI) to another are currently
excluded, in part because of the logistical difficulties in
collecting the time of arrival at one center and the time of
reperfusion in another and a lack of consensus on the
appropriate attribution of a measure that involves more than
1 institution. As a result, however, an important segment of
the patient population that receives reperfusion is systemati-
cally excluded from the measure. Furthermore, centers that
uniformly transfer patients for primary PCI are thus not
included in the current reperfusion measures.
Second, there are many clinically sound reasons why
clinicians may not pursue a primary reperfusion strategy in
patients with STEMI. Among those patients who receive
reperfusion after the guideline-recommended time threshold
(30 minutes for fibrinolysis or 90 minutes for PCI), docu-
mented clinical reasons justifying a delay in reperfusion
therapy qualify as an exclusion from the measure denomina-
tor. Because it is often difficult to infer what clinicians are
thinking based on the medical record, rules have been
developed to ascertain this conclusion. For practical pur-
poses, these rules cannot require clinical judgment regarding
the documented reason for delay. With the exception of a
small number of discrete events that consistently result in
significant but clinically appropriate reasons for delay (eg,
cardiac arrest), the reason must also be explicitly linked in the
records documentation to a delay in providing reperfusion.
Finally, the exclusion applies only to patient-related reasons
for a delay in the provision of reperfusion therapy (eg, refusal
to provide consent for PCI) and not system-centered reasons
(eg, catheterization laboratory staff late to arrive). System-
centered reasons for delay are not permitted because these are
the very issues that measurement is intended to identify and
eliminate.
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This exclusion is intended to account for frequently en-
countered scenarios in clinical care, such as the performance
of diagnostic tests to exclude an alternative diagnosis or
contraindication to therapy. However, this exclusion does not
allow for the assessment of care in those patients who receive
optimally timely therapy after the reason for delay has been
resolved, because it is not practical to identify the appropriate
“start” time in such patients with standard chart documenta-
tion. At the same time, there are concerns about the potential
for overdocumentation of reasons for delay, in part because
the validity of documented reasons cannot be considered
practically in records abstraction. Currently, data are not
available to determine the variation in the documentation of
delays of reperfusion therapy.
Importantly, assessment for patient-centered reasons for
delay is only applied to those patients for whom reperfusion
was provided outside of the guideline-recommended time
threshold. An important reason for this approach is that it
substantially reduces the abstraction burden by obviating the
assessment of delays in patients who receive timely therapy.
This approach has variable implications on the measures of
the proportion of patients receiving therapy compared with
the measures of the median reperfusion time. Specifically, a
patient who received PCI in 85 minutes after a delay of 25
minutes for the purposes of performing imaging to exclude
acute aortic dissection would contribute positively to the
measure of the proportion of patients receiving PCI within 90
minutes; however, the time of 85 minutes, which includes the
25-minute delay, would contribute to the institutional median
time calculation.
Finally, the measure excludes those patients for whom PCI
was not used as a primary reperfusion strategy. Thus, for
example, patients who undergo PCI after first receiving
fibrinolytic therapy (eg, “rescue” PCI) or those whose symp-
toms and ST elevation resolve early after presentation and
before PCI are excluded if the documentation is adequate to
ascertain that the PCI was not part of a primary reperfusion
strategy. These exclusions are intended to enhance the degree
to which the measure denominator includes only those
patients for whom PCI is the primary reperfusion strategy.
However, the construction of a data element suitable for
abstraction that accounts for the variation in terminology that
might be used in clinical documentation to describe these
situations and that simultaneously limits the inappropriate
exclusion of patients who receive primary PCI has been
challenging.
4.2.1. Measures Exclusions—Work Group
Conclusions
1. An additional measure that includes patients who are
transferred from one hospital to another for the purposes
of receiving reperfusion should be developed and imple-
mented (see below).
2. An exclusion that accounts for patient-centered reasons for
delaying reperfusion therapy is clinically necessary; how-
ever, surveillance to assess the extent to which this
exclusion is used (and potentially overused) will be
important to determine the impact of this exclusion on
patient care and whether this exclusion is practical to
maintain. Specifically, this surveillance should include the
frequency distribution of the application of this exclusion
among centers to identify outliers. There should also be an
audit mechanism to determine the clinical appropriateness
of delays among records in which this exclusion was
applied; this audit process should be transparent and
should include components that are systematic (eg, among
all outliers) and random. Finally, a means of adjudicating
audit failures is a necessary component of an audit
process.
3. The exclusion of patients who receive PCI that is not part
of a primary reperfusion strategy is also appropriate;
however, an audit process to assess the extent of the use of
this exclusion would also be appropriate.
4. The intensity of audit efforts (items 2 and 3 above) will
depend on the purpose of the measure, with effective audit
processes dedicated to measures used for the purposes of
public accountability and/or reimbursement. An audit
process may be unnecessary for measures used solely for
the purposes of quality improvement.
5. As times to reperfusion decline nationally, the assessment
of patient-centered reasons for delay should be considered
for all records rather than the current restriction to those
cases for which reperfusion is provided outside of the
standard guideline-recommended time window. Given
current rates of performance, and acknowledging the
abstraction burden that this change would represent, the
work group does not currently endorse this change.
4.3. Time of Device Use for PCI
The determination of the time of PCI (ie, when measurement
stops) is central to the reperfusion measure. The commonly
used term “door-to-balloon time” has decreasing clinical
relevance with the proliferation of additional devices used to
establish reperfusion for STEMI (eg, stents and thrombec-
tomy devices). The current measure specifications, which
acknowledge this growing complexity, consider the first use
of any device primarily intended to result in reperfusion as the
“balloon” time. Several aspects of this approach to the
measures should be considered.
First, with respect to identifying the time at which mea-
surement both starts and stops, various sources of clock time
may be used, including ECG machines, emergency depart-
ment documentation, and catheterization laboratory logs. The
lack of synchronization of the clocks integral to establishing
time landmarks for the reperfusion measures will result in the
misclassification of the time to reperfusion due to errors in the
accurate identification of the start time, end time, or both.
Ultimately, accurate system-wide timekeeping has important
implications not only for measures of the time to reperfusion
for STEMI but also for other measures of performance (eg,
timing of antibiotics for pneumonia) and other important
aspects of patient care. Thus, synchronization of timekeeping
devices to an external standard is an important goal for health
systems.
Second, although the measure accounts for evolving tech-
nology, it does not identify the time at which reperfusion is
established. For example, in cases in which the angiogram
initially demonstrates normal or near-normal flow in the
infarct-related artery or in which a wire, guiding catheter, or
contrast injection reestablishes flow, the current measure
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specification mandates that the time of angiography or wire
insertion is not considered the time of treatment. Conversely,
however, the measure does not require that the first attempt at
reperfusion be successful to count toward the time of PCI.
Thus, the current measure should be considered a measure of
a process (ie, delivering a device intended to result in
reperfusion) rather than an outcome (ie, normal coronary
flow).
There are specific advantages of using the process of
device use over the outcome of successful reperfusion. First,
the approach is consistent with the underlying guideline
recommendation that the “door-to-balloon” time in patients
with STEMI should be less than 90 minutes. Second, whereas
the time of device use is a factor that can usually be identified
by nonclinical abstractors, the ascertainment of adequate flow
in the infarct-related artery raises substantial concerns regard-
ing abstraction burden and reliability. Finally, it does not
generate a penalty in those situations in which flow cannot be
restored despite appropriate and timely treatment.
On the other hand, the use of device time has disadvantages
as well. First, because the goal of primary PCI is to restore
flow in the infarct-related artery, there is face validity to the
measurement of this time. Second, in cases in which adequate
flow is present spontaneously or results from the use of a
wire, the operator may use more time in the consideration of
the approach to device therapy without significant adverse
consequences for the patient.
Alternative approaches were also considered, including
measurement of door-to–catheterization laboratory time or
door-to–first angiogram time. The advantages of these ap-
proaches are that the times are typically easier to determine
from the medical record, the need to ascertain reasons for
delay after angiography is obviated, and these constructions
render the discussion about device use versus flow restoration
moot. However, these approaches do not account for the
importance of care provided within the catheterization labo-
ratory and are not consistent with guideline recommenda-
tions, which focus on the total time from presentation to PCI.
4.3.1. Time of Device Use for PCI—Work
Group Conclusions
1. Systems that provide reperfusion therapy should synchro-
nize all devices (eg, ECG machines and electronic cathe-
terization laboratory documentation systems) involved in
establishing time landmarks in the reperfusion measures to
a consistent external standard (eg, satellite synchroniza-
tion with atomic clocks).
2. After consideration of the relative benefits and limitations
of the various approaches, the work group supports a
measure that focuses on the time of first device use rather
than the time of restoration of flow or the time of other
“upstream” events (eg, time to first angiography).
5. Proposals for Future Measures of
Time to Reperfusion
As discussed above, the existing measures focus on the time to
reperfusion among treated patients without specific documented
exclusions; however, these measures do not address other
important aspects of the delivery of reperfusion therapy. Ulti-
mately, the family of measures that focus on reperfusion should
be aligned with guidelines, which both recommend strategies of
care and emphasize the importance of time in implementing
these strategies. These measures should also be comprehensive,
addressing decision making about the delivery of reperfusion in
potential candidates for therapy and including as many eligible
patients as possible in measurement. To expand the extent to
which measurement provides a comprehensive assessment of
the approach to therapy, the work group proposed recommen-
dations for the development of 3 additional measures. These
recommendations will be provided for consideration to the
ACC/AHA Performance Measures Task Force, which has de-
veloped process performance measures for the care of patients
with acute myocardial infarction (10).
5.1. Time to Reperfusion Among Patients
Transferred for PCI
The current CMS and Joint Commission reperfusion perfor-
mance measures exclude patients who are received in transfer
from other acute care institutions. As a result, care provided by
those hospitals that routinely transfer patients with STEMI for
primary PCI is not included in the measures of time to PCI.
However, the time to PCI is equally important in patients
who are transferred from one institution to another, and the
process of transfer has the potential to prolong the time to
PCI. In the current era, total door-to-balloon time for these
transferred patients is less than 2 hours in a little more than a
quarter of patients, between 2 and 4 hours in a little more than
half of patients, and 4 hours or greater in about 20% of patients
(19). There are many ways to improve these times. In hospitals
that do not have PCI facilities, it is important to know the
expected time to primary PCI if they transfer the patient in order
to make the best treatment decisions for those who are eligible
for fibrinolytic therapy. Moreover, knowledge of these times is
critically important to the development of strategies to eliminate
delays. In settings where geographic barriers make it difficult to
transfer patients quickly, it is still important to know what times
are being achieved as a means to assess decision-making and to
focus on whether there are any opportunities to reduce any
unnecessary wait times. It is difficult to identify a precise time
beyond which there is an unacceptable delay, but knowledge of
the times is central to improving the systems of transfer. The
intent of such a measure is to illuminate performance from the
patient’s perspective. Because of the value of understanding
the care for patients who are transferred for this time-sensitive
therapy, the work group recommends that such patients be
included in additional measures. This should include mea-
sures of 1) time from presentation to discharge in the
presenting institution (“door-in/door-out”) and 2) time from
presentation at the first facility to time of PCI in the receiving
facility (“first-door-to-PCI”). This recommendation is made
with acknowledgment of the following considerations in
development and implementation:
1. Historically, patients who were transferred were excluded
because of the difficulty in ascertaining the time of
presentation at one institution and the time of PCI in
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another. Specific approaches to addressing this barrier
should be considered. Of note, this issue is not relevant to
a “door-in/door-out” measure.
2. Issues of identifying the provider responsible for the
results (ie, attribution) and reporting should be addressed
during measure development. It should be specified
whether performance on this measure should be attributed
to the transferring institution, the receiving institution, or
both institutions. Additionally, if attributable to the receiv-
ing institution in whole or in part, it should be specified
whether patients received in transfer should be reported
separately. The present writing group advocates attribu-
tion to both facilities.
3. The times to PCI for patients who are transferred for
reperfusion should be reported separately from times for
those who are not transferred.
4. In cases in which a patient has a contraindication to reperfu-
sion therapy, the clinician does not have the option of
considering fibrinolysis rather than transfer, even if the
transfer will be delayed. Thus, reporting of the time to PCI in
patients who are transferred should be stratified by the
presence or absence of contraindications to fibrinolytic
therapy.
5.2. Proportion of Reperfusion-Eligible
Patients Receiving Therapy
Measuring the time to reperfusion among patients who
receive this therapy does not address the decision to provide
reperfusion therapy among eligible patients. Recent data
suggest that although the proportion of eligible patients
receiving therapy has increased significantly over time, gaps
in this process of care persist (20). The work group thus
proposed the development of a measure that would quantify
the proportion of those patients who are eligible for therapy.
This recommendation is made with acknowledgment of the
following barriers to development and implementation:
1. The element defining the ECG criteria for inclusion in the
denominator of this measure must be more explicit than that
used for the current measures and must conform more
exactly to the ECG criteria requirements specified by the
guidelines. Because the existing measure specifically in-
cludes those patients who receive some form of reperfusion
therapy, failures in the specificity of the ECG element have
limited impact on measurement. However, a measure that is
intended to identify patients who should have received
therapy places greater emphasis on the specificity of the
criteria used to identify the denominator. The current mea-
sures require relatively general mention of ST-segment ele-
vation or ECG evidence of myocardial injury, whereas a
measure identifying reperfusion-eligible patients would re-
quire the identification of ST elevation greater than 0.1 mV in
at least 2 contiguous precordial leads or at least 2 adjacent
limb leads, as recommended in the guidelines (21). The need
for this greater detail must be balanced with the greater
burden of abstraction and feasibility of abstraction at this
level of detail by nonclinical staff.
2. Contraindications that would disqualify patients from
these measures must be considered, particularly for fi-
brinolytic therapy, for which the adverse consequences of
treatment in patients with contraindications are substan-
tial. This includes consideration of whether a discrete list
of absolute contraindications should be developed rather
than relying solely on the explicit documentation of a
contraindication to therapy.
3. The impact of more specific ECG criteria (point 1 above)
and contraindication definitions (point 2 above) on the
institution-level sample size must be assessed during
measure testing. By reducing the numbers of patients
included in the measure, these factors may limit applica-
bility, especially to relatively low-volume centers.
4. Concurrent assessment of the provision of fibrinolysis or
coronary angiography in patients not meeting guideline
criteria for reperfusion (“overuse” and “false-positives”) could
inform internal institutional quality improvement. The writ-
ing group acknowledges the challenges of identifying such
cases reliably from retrospective abstraction of clinical data.
5.3. Time From First Medical System Contact
to Reperfusion
Beginning in 2004, the ACC/AHA STEMI guideline recom-
mendations for both fibrinolysis and primary PCI recommend
that patients receive therapy within a limited time from first
medical system contact rather than from the time of presen-
tation at an acute care facility (1,22). However, the current
time-to-reperfusion measures reported by CMS and the Joint
Commission and those endorsed by the ACC/AHA use the
time of hospital presentation as the “start time.” The time of
hospital presentation at a healthcare institution has been used
as the index time for several reasons. Practically, systematic
approaches to collecting data on the time of first system
contact have not been assessed or validated, whereas the time
of presentation at an institution is routinely available in
records. Furthermore, the appropriate definition of first med-
ical system contact (eg, emergency medical services system
activation versus time of first in-field ECG) is a topic of
substantial debate. The use of time of presentation, the
standard that has been used in previous measures, also
provides consistency across time. Finally, issues of account-
ability with the time of first system contact are substantially
more complicated than those surrounding the current reper-
fusion measures. Specifically, because current public report-
ing efforts focus on institutions rather than systems, measures
that include the time from first system contact could poten-
tially penalize institutions for issues beyond their control.
The work group acknowledges, however, that the goal of
evolution toward measuring the time of first system contact to
reperfusion is appropriate for several reasons. First, with
evolving health information technology, determining the time
of first system contact is likely to become easier and more
consistent. Second, the measures should remain consistent
with guidelines whenever possible, presuming that practical
barriers can be overcome. Finally, as systems of care to
provide reperfusion proliferate (23,24), an understanding of
the performance of these systems becomes increasingly
important. Measuring the performance of systems is likely to
foster the collaboration among multiple systems, including
emergency medical services, that is necessary to ensure
optimal quality of care.
Although the work group agrees that performance measure-
ment should migrate toward an approach of using the time of
first system contact, it currently advocates the development of
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such measurement for quality-improvement purposes rather than
for public reporting, with an explicit goal of addressing the
issues described above as part of the implementation process.
Such implementation testing would lay the foundation for the
use of measures of time from first system contact to reperfusion
as measures for the purposes of public accountability.
5.4. Time to Reperfusion for Patients
Developing STEMI in the Hospital
The current CMS and Joint Commission reperfusion measures
exclude those patients without ST-segment elevation or left
bundle-branch block on the ECG closest to the time of arrival.
Thus, those patients with STEMI who develop pathological
ECG abnormalities after presentation with an ECG that does not
show ST-segment elevation or left bundle-branch block either in
the emergency department or initially at admission do not
contribute to the measurement. Given that the institutional
capacity to address the care of such patients in a timely manner
may vary based on the manner of presentation, understanding
the care of this patient population would be valuable for the
purposes of quality improvement. This recommendation is made
with the acknowledgment that measurement in this population
requires further testing before it can be recommended for
incorporation in external reporting.
The appeal of restricting the reperfusion measures to those
patients with STEMI on emergency department presentation
lies in the ease of identifying the “start time” from the
perspective of the system (ie, time of hospital arrival). The
measure should include explicit recommendations regarding
the means of identifying the measure start time, with ac-
knowledgment of the possibility of inaccuracies of ECG time
stamps among institutions and the potential challenges of
ascertaining event timing from progress notes and other types
of documentation.
6. Future Considerations for Measuring
Time to Reperfusion: Electronic Health
Records and Clinical Registries
Ultimately, many of the central challenges in measuring the time
to reperfusion and the barriers to expanding measurement to
broader populations derive from the difficulty in obtaining the
underlying data from chart abstraction of markedly variable
sources of information. Advances that successfully reduce the
burden and increase the accuracy of data abstraction thus have
the capacity to revolutionize the measurement of clinical perfor-
mance around the time to reperfusion.
Electronic health records (EHRs) provide a platform for
automated data collection, with the potential to reduce ab-
straction time and increase the fidelity of data abstraction. A
recent study, however, moderates any enthusiasm that EHRs
represent a panacea to the challenges of the problems of
measuring quality of care (25). The study assessed the quality
of outpatient heart failure care and found that an EHR had
limited sensitivity for clinically important contraindications
to therapy, which resulted in important underestimates of
clinical performance. This finding emphasizes the importance
of considering performance measurement in the development
of EHRs, with an emphasis on data standardization and the
inclusion of specific data elements that underlie the assess-
ment of clinical performance.
Finally, clinical data registries and quality-improvement
initiatives (eg, NCDR and Get With the Guidelines) have the
potential to facilitate assessment of the quality of care.
Beyond the importance of data standardization, 2 additional
issues are specifically germane to registries. First, the extent
to which registries are adopted will depend in large part on
the integration of the registry within clinical care in real time.
Duplicative data entry raises barriers to participation and may
diminish the accuracy of the data collected, which may be
compounded if data entry in different sources is performed by
different personnel. Second, the specifications developed for
clinical registries and quality-improvement initiatives should
maintain alignment with existing measures whenever possi-
ble, particularly those already in use for public reporting.
Failure of alignment creates confusion regarding the specifi-
cations of the measures and “measurement fatigue.”
National clinical data registries and quality-improvement
initiatives also create important opportunities for improving
performance measurement. First, these efforts can be used to
pilot test measures before widespread implementation, which
would facilitate the identification of specific barriers to imple-
mentation and the refinement of data-element definitions. Sec-
ond, as with EHRs, registries can be used to collect specific
encoded clinical data elements, which enhances the clinical
validity of performance measures and decreases the burden of
ascertaining the data necessary to calculate performance.
Thus, EHRs and clinical registries have important potential
for transforming performance measurement. In the future, the
widespread implementation of these innovations has the
potential to generate a more accurate and broader understand-
ing of the delivery of life-saving therapy in practice and to
facilitate the provision of the right treatment for the right
patient in a timely manner.
7. Conclusions
Because of the substantial impact of acute reperfusion on
outcomes after STEMI and an understanding of the signifi-
cant room for improvement, increasing attention has been
focused on the measurement of care for patients receiving this
critical therapy. Over the last decade and a half, national
quality assessment and public reporting efforts have mea-
sured the time to reperfusion for fibrinolysis and PCI using
metrics that have evolved over time. The work group, the
deliberations of which are summarized here, reviewed the
existing measures with recommendations for modifications to
optimize the performance and acceptance of these measures.
Furthermore, this group provided recommendations for ex-
panding the scope of the measurement of the process of
reperfusion therapy. These recommendations are provided
with the recognition that any measure, new or old, will not
perform perfectly when implemented. Despite any limita-
tions, however, formal assessment of the process of deliver-
ing reperfusion is necessary to understand what must be done
to achieve the common goal of optimizing patient outcomes.
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Appendix A. Inclusion and Exclusion Criteria for
CMS and the Joint Commission Reperfusion
Measures (Effective 10/1/08–3/31/09
Discharges)
Table A1. Inclusion Criteria for CMS and the Joint
Commission Reperfusion Measures
PCI
ICD-9-CM principal diagnosis code of AMI and
ICD-9-CM procedure code of PCI and
ST-segment elevation or LBBB on ECG performed closest to arrival* and
PCI performed within 24 hours of arrival
Fibrinolysis
ICD-9-CM principal diagnosis code of AMI and
ST-segment elevation or LBBB on ECG performed closest to arrival* and
Fibrinolytic therapy performed within 6 hours of arrival and
Fibrinolysis is the primary reperfusion therapy
AMI indicates acute myocardial infarction; CMS, Centers for Medicare &
Medicaid Services; ECG, electrocardiogram; ICD-9-CM, International Classifi-
cation of Diseases 9th Revision Clinical Modification; LBBB, left bundle-branch
block; and PCI, percutaneous coronary intervention.
*Per the CMS and the Joint Commission data-element definitions.
Table A2. Exclusion Criteria for CMS and the Joint
Commission Reperfusion Measures
PCI
Patients less than 18 years of age
Patients who have a length of stay greater than 120 days
Patients with comfort measures only documented on day of or day after
arrival
Patients enrolled in clinical trials
Patients received as a transfer from an acute care facility where they
were an inpatient or outpatient
Patients received as a transfer from one distinct unit of the hospital to
another distinct unit of the same hospital
Patients received as a transfer from the emergency department of
another hospital
Patients administered a fibrinolytic agent prior to PCI
PCI described as nonprimary by a physician/APN/PA
Patients who did not receive PCI within 90 minutes and had a reason for
delay documented by a physician/APN/PA (eg, social, religious, initial
concern or refusal, cardiopulmonary arrest)
Fibrinolysis
Patients less than 18 years of age
Patients who have a length of stay greater than 120 days
Patients with comfort measures only documented on day of or day after
arrival
Patients enrolled in clinical trials
Patients received as a transfer from an acute care facility where they
were an inpatient or outpatient
Patients received as a transfer from one distinct unit of the hospital to
another distinct unit of the same hospital
Patients received as a transfer from the emergency department of
another hospital
Patients who did not receive fibrinolytic therapy within 30 minutes and
had a reason for delay documented by a physician/APN/PA (eg, social,
religious, initial concern or refusal, cardiopulmonary arrest)
APN indicates advanced practice nurse; PA, physician assistant; and PCI,
percutaneous coronary intervention.
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